# US 2020/0399341 A1 · The compbody - a multivalent target binder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399341 A1
- Document ID: US20200399341A1
- Status: Published application
- Kind: A1
- Application number: 16/861,496
- Filed: 2020-04-29
- Published: 2020-12-24
- Earliest claimed: 2017-11-01
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Guy Georges; Josef Platzer
- Web page: https://patentgrep.com/patent/US20200399341A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 16/22: against growth factors {; against growth regulators}
- C12N 15/66: General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/55: Fab or Fab'
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Herein is reported a multimeric fusion polypeptide comprising five monomeric fusion polypeptides each comprising at least a Fab fragment and a COMP-domain of SEQ ID NO: 01 or a functional fragment thereof.

## Claims

### Claim 1

A multimeric, multispecific fusion polypeptide
comprising five monomeric fusion polypeptides each comprising at least a Fab and a COMP-domain of SEQ ID NO: 01 or a fragment of the COMP-domain of SEQ ID NO: 01 that can associate with other COMP-domains.

### Claim 2 (depends on 1)

The multimeric fusion polypeptide according to claim 1, wherein the Fab is conjugated either directly or via a peptidic linker to the COMP-domain independently of each other for the five monomeric fusion polypeptides.

### Claim 3 (depends on 1, 2)

The multimeric fusion polypeptide according to any one of claims 1 to 2, wherein the COMP-domain is conjugated to a C-terminus or an N-terminus of the Fab independently of each other for the five monomeric fusion polypeptides.

### Claim 4 (depends on 1, 2, 3)

The multimeric fusion polypeptide according to any one of claims 1 to 3, wherein the Fab is selected from a Fab, a scFab, a bispecific Fab and a DAF.

### Claim 5 (depends on 1, 2, 3)

The multimeric fusion polypeptide according to any one of claims 1 to 3, wherein the Fab is a half-antibody.

### Claim 6 (depends on 5)

The multimeric fusion polypeptide according to claim 5, wherein the half-antibody is a dimeric half antibody wherein one monomer comprises the hole mutations and the respective other monomer comprises the knob mutation.

### Claim 7 (depends on 6)

The multimeric fusion polypeptide according to claim 6, wherein the first half antibody binds to a first antigen and the second half antibody binds to a second antigen (bispecific antibody).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method for the preparation of the multimeric fusion polypeptide according to any one of claims 1 to 7, comprising the steps of
transforming a host cell with expression vectors comprising nucleic acids encoding the multimeric fusion polypeptide,
culturing said host cell under conditions that allow synthesis of said multimeric fusion polypeptide, and
recovering said multimeric fusion polypeptide from said host cell culture.

### Claim 9 (depends on 8)

A multimeric fusion polypeptide produced by the method according to claim 8.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

A nucleic acid encoding the multimeric fusion polypeptide according to any one of claims 1 to 7.

### Claim 11 (depends on 10)

An expression vector comprising a nucleic acid according to claim 10.

### Claim 12 (depends on 10)

A host cell comprising a nucleic acid according to claim 10.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7)

A pharmaceutical composition comprising the multimeric fusion polypeptide according to any one of claims 1 to 7 in combination with at least one pharmaceutically acceptable carrier.